Canada Goose beats estimates, pulls full-year guidance on 'macroeconomic uncertainty'
Shares of Canada Goose rose around 8% on Wednesday after the company reported fiscal fourth-quarter earnings that beat analysts' estimates, though the company pulled its fiscal year 2026 outlook due to "macroeconomic uncertainty."
The luxury retailer said it will not be providing a financial outlook for the fiscal year 2026 due to the uncertainty, citing "dynamic consumer spending patterns brought on by the unpredictable global trade environment."
Nonetheless, Canada Goose said it "remains confident in the strength of the brand, the Company's solid financial position, and its ability to adapt to changing conditions."
Here's what the company reported for the fiscal fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
Canada Goose's revenue was up 7.4% from the same period last year.
Net income attributable to shareholders for the fiscal fourth quarter ending March 30 was CA$27.1 million, or 28 Canadian cents per diluted share, compared with a net income attributable to shareholders of CA$5 million, or 5 Canadian cents per diluted share in the prior year period.
As of Monday's close, shares had fallen nearly 14% year to date, hitting an all-time low last month after Barclay's analysts downgraded the stock and cut their price target.
The luxury sector as a whole has shown signs of weakness, with major luxury players like LVHM, Burberry and Gucci-owner Kering reporting a slowdown in sales in the quarter.
Canada Goose, known for its luxury parkas and puffer jackets that can retail for over $1,000, has tried to expand into the non-winter category by offering products like rain jackets and warm-weather clothing.
Its eyewear collection, introduced in the fourth quarter, was the company's first online product launch. The retailer called the launch a "key milestone" in its "product category expansion journey."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Viemed Healthcare Announces Share Repurchase Program
LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ('the Common Shares') from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase. Casey Hoyt, Viemed's Chief Executive Officer, noted, 'Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business. We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan's Medical that is expected to close in the third quarter of this year. Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies. With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives.' The price paid for the Common Shares will be the market price at the time of purchase, plus applicable brokerage fees, or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of Common Shares that will be repurchased under the program, if any. The Company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The Common Shares purchased by the Company will be cancelled. ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at statements contained in this press release may constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'potential', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'projects', or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results 'will', 'should', 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations regarding the amount and timing of any potential repurchases of Common Shares, the funding sources for such repurchases, the availability of Common Shares for such repurchases, and the anticipated benefits to shareholders of such repurchases, as well as about its pending acquisition of Lehan's Medical Equipment, such as expected purchase price, contingent payments, closing date, funding sources, and anticipated synergies and other benefits are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the 'SEC') available on the SEC's website at including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. For further information, please contact: Investor Relationsir@ Tripp SullivanSCR Partners, LLC615-942-7077 Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802
Yahoo
34 minutes ago
- Yahoo
Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering
MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ('Nuwellis' or the 'Company'), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock ('Common Stock'), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock. The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $0.2999 per pre-funded warrant and accompanying warrants. Nuwellis expects to use the net proceeds from the offering for working capital and general corporate purposes, including possible acquisition activity. Each pre-funded warrant has an exercise price of $0.0001 per pre-funded warrant, and is immediately exercisable until such pre-funded warrant is exercised in full. Each of the Series A Warrants and Series B Warrants has an exercise price of $0.30, and will be exercisable for a period of five years following the receipt of stockholder approval, as required by the applicable rules and regulations of Nasdaq. The Series A Warrants will contain a one-time reset of the exercise price in the event that the Company implements a reverse stock split to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in this offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of a reverse stock split. The Series B Warrants will include a zero cash exercise option allowing holders of a Series B Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series B Warrant. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the offering. The offering is expected to close on or about June 10, 2025, subject to customary closing conditions. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-287663) that was declared effective by the U.S. Securities and Exchange Commission ('SEC'), on June 9, 2025. Electronic copies of the final prospectus supplement may be obtained, when available, on the SEC's website at or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering will be filed by Nuwellis with the SEC. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical device company focused on transforming the lives of patients with fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X. About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the receipt of stockholder approval to permit the exercise of the Series A Warrants and Series B Warrants, the satisfaction of customary closing conditions related to the offering, the expected closing date of the offering and the amount and expected use of the net proceeds from the offering. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'continue,' 'intends to,' 'expect,' 'will,' 'goal,' 'aim to' and similar expressions. Such forward-looking statements include, among others, statements regarding the Company's anticipated closing of the public offering. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: INVESTORS: Robert Scott Chief Financial Officer, Nuwellis ir@ MEDIA CONTACT: Leah McMullen Director of Communications, Nuwellis Source:Nuwellis in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
EDC supported more than 27,800 businesses and facilitated more than $123 billion intrade-related activities
Canada's export credit agency releases its 2024 business results and ESG performance reports OTTAWA, ON, June 9, 2025 /CNW/ - Today, Export Development Canada (EDC) released its 2024 Integrated Annual Report, highlighting how the organization helped its customers grow their business beyond Canada to seize the vast trade opportunities that await them in the global marketplace. The report is complemented by additional environmental, social and governance (ESG) disclosures: 2024 Climate-Related Disclosure, and the 2024 Sustainable Bond Impact Report. In 2024, exporters faced a complex and rapidly evolving economic environment. During this period, EDC expanded its presence in key Indo-Pacific markets to support the trade diversification of Canadian exporters. EDC invested in medium-sized Canadian exporters, sharpening its focus on priority sectors, and maintained a strong commitment to sustainable and responsible business practices. "In 2024, global economic softness weighed on Canadian exporters. Slow domestic growth, higher-for-longer interest rates and slowing labour markets strained the economic outlook in many countries," said Alison Nankivell, EDC's President and CEO. "Those challenges, coupled with new market uncertainties towards the end of the year, have energized our customers to transition from continental to global traders as we strive to make it easier for them to secure new international business opportunities. This renewed interest in trade diversification and EDC's solutions have increased since the start of this year given the evolving nature of U.S. trade policies, and we're stepping up to support them." In 2024, EDC supported more than 27,800 customers with financial and knowledge solutions, with the vast majority being small and medium-sized businesses. We facilitated a total of $123.4 billion in exports, foreign investment and trade development activities, including $23.4 billion in business in emerging markets. This support contributed to over 475,800 domestic jobs and helped to generate $87 billion of Canada's GDP. "During an uncertain economic environment, we strategically deployed capital and took on risk to help more Canadian companies reach global markets—and we are continuing to do so in response to the current climate," said Scott Moore, EDC's Executive Vice-President and Chief Financial Officer. "We're motivated by findings that Canadian companies supported by EDC generate 23% more revenues, employ 16% more workers and are 6% more productive, according to our latest study with Statistics Canada." In 2024, EDC's net income increased to $915 million from $450 million in 2023. This was driven by higher net revenue, combined with unrealized gains on financial instruments carried at fair value. Our growing presence in the Indo-Pacific In 2024, EDC added three new representations in the Indo-Pacific, increasing the total number of representations to 11 in the region, including its Singapore branch. EDC opened representations in Ho Chi Minh City, Vietnam, Manila, Philippines, and most recently, Bangkok, Thailand (in 2025) to offer in-market support to attract more Canadian companies to the booming region and help them navigate local market complexities. EDC supported 1,529 customers and facilitated $13 billion in business volumes in the Indo-Pacific region in 2024. It also signed memorandums of understanding with several export credit agencies and market leaders to enable strong market access for Canadian exporters. Our support for Canada's medium-sized exporters and key sectors In 2024, we continued our strategic objective to support the international growth of Canada's medium-sized companies. In 2024, we served 1,175 medium-sized Canadian companies across our financial solutions. EDC is focusing on Canadian sectors that provide net-new growth for Canada, namely agri-food, critical minerals, the energy transition, advanced manufacturing and digital industries. Its goal is to highlight Canada's strengths on the global stage and improve trade competitiveness. For example, in the agri-food sector, EDC served 3,201 customers throughout the year, facilitating $21.7 billion in business. As a leading financier of Canada's cleantech industry, EDC served 500 cleantech customers in 2024, enabling $9.7 billion in business facilitated. Our commitment to responsible business Throughout the year, EDC maintained its commitment to responsible business. In 2024, we issued our sixth green bond valued at US$ 1 billion, helping to further attract capital for climate-focused investment and support for projects that generate positive environmental outcomes. Additionally, we deployed $1.3 billion in financing for 56 renewable energy projects. Through our inclusive trade efforts, we offered targeted support for Canadian companies owned by members of equity-seeking groups, focusing on companies owned by women and Indigenous people. This effort served 3,816 financial and non-financial customers and facilitated $2.5 billion in business and trade activities. For more information, read the 2024 Integrated Annual Report and the suite of supplemental ESG reports. About EDC Export Development Canada (EDC) is a financial Crown corporation dedicated to helping Canadian businesses make an impact at home and abroad. EDC has the financial products and knowledge Canadian companies need to confidently enter new markets, reduce financial risk and grow their business as they go from local to global. Together, EDC and Canadian companies are building a more prosperous, stronger and sustainable economy for all Canadians. For more information and to learn how we can help your company, call us at 1-800-229-0575 or visit SOURCE Export Development Canada View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
